Drugs / Tenofovir Disoproxil Fumarate/Emtricitabine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03060785 | Mar 2016 → May 2018 | — | Johns Hopkins University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tenofovir Disoproxil Fumarate/Emtricitabine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03060785 ↗ |
| Route | Oral | “Single daily dose of oral Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) for 7days in cis men” NCT03060785 ↗ |